The biology of MUC1 is complex, however, early trials in cancer, where MUC1 is a well-studied tumour-associated antigen, suggest that monoclonal antibodies or inhibitors of MUC1 might represent a new therapeutic avenue for IPF (35). Here, MUC1 is linked to neoplasm.